Safeguarding our people and communities remains our top priority. 03 Apr 2020 As the COVID-19 pandemic evolves, we are continuing to take steps to ensure the health and safety of our workforce and...

This news release is intended for medical and pharmaceutical trade media and financial media only 31 Mar 2020 Seqirus, a global leader in influenza prevention, today announced that its adjuvanted...

To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing. By Anthony Farina – Chief Communications Officer, CSL Limited | 23 Mar 2020...

Seqirus, a global leader in influenza prevention, announced today that its cell-based quadrivalent influenza vaccine (QIVc) has received approval from Health Canada for use in people 9 years of...

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine...